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To date, the role of miRNA in tumorigenesis has been largely reported. It was found that miR-181a may
be involved in the tumorigenesis of colon cancer. The purpose of this study was to investigate the
mechanism of miR-181a in colon cancer carcinogenesis. The expression levels of IL-1b, NF-kB (RelA), and
miR-181a in colon cancer tissue were higher than that in normal control tissue when assessed by real-
timePCR. In addition, it was found that IL-1b induced the expression of miR-181a. The expression of PTEN
was regulated by IL-1b-stimulated miR-181a expression. In a PTEN reporter plasmid, miR-181a binding
site mutations were introduced. By using a luciferase reporter assay, it was found that wild type reported
activity was lower than that of the mutant registration system activity. Furthermore, a siRNA strategy
was used to ﬁnd that IL-1B regulates miR-181a expression via NF-kB and then regulates PTEN expression.
Consequently, repression of PTEN by miR-181a promotes colon cancer cell proliferation. Taken together,
our data support a critical role for NF-kB-dependent upregulation of miR-181a; this represents a new
pathway for the repression of PTEN and the promotion of cell proliferation upon IL-1b induction.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is a worldwide disease that is the third
most common cause of cancer in both women and men and is also
the third most common cause of cancer death [1]. Inﬂammation
plays a major role in CRC development, including tumor initiation,
progression, and invasion [2]. Numerous factors have been regar-
ded as potential diagnostic and prognostic markers in CRC [3].
Continuous exposure to inﬂammatory cytokines, includingIL-1, IL-
6, and TNF-a, is known to initiate CRC [4,5].
The nuclear factor kappa B (NF-kB) family members share
structural homology with the retroviral onco-protein v-Rel result-
ing in their classiﬁcation as NF-kB/Rel proteins [6]. There are ﬁve
proteins in the mammalian NF-kB family: NF-kB1, NF-kB2, RelA,
RelB, and c-Rel. The NF-kB pathway has long been considered a
major pro-inﬂammatory signaling pathway largely based on the
activation of NF-kB by pro-inﬂammatory cytokines and the role of
NF-kBin the transcriptional activation of responsive genes
including cytokines and chemokines [7,8]. The “canonical” pathwaycology, Xiangya Hospital,
, Hunan 410008, PR China.
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Inc. This is an open access article ufor NF-kB activation is triggered by pro-inﬂammatory cytokines,
such as IL-1b. NF-kB has been reported to be activated by IL-1bin
intestinal epithelia cells and colorectal adenomas in azoxy-
methane- or dextran sulfate sodium-induced mice as well as in
colon cancer cell lines [9,10]. Thus far, however, the role of the IL-
1b/NF-kB signal pathway in colon carcinogenesis has not been
characterized.
NF-kB induces a variety of biological processes through tran-
scriptional gene control in various signaling pathways including
several miRNAs [11]. Xu et al. reported that DNA damage-induced
NF-kB activation in human glioblastoma cells promotes miR-181b
expression and cell proliferation [12]. NF-kB signaling pathway
regulates the miR-223/FBXW7 axis in T-cell acute lymphoblastic
leukemia (T-ALL) and regulates T-ALL resistance to gamma-
secretase inhibitor (GSI) treatment [13]. In addition, NF-kB modu-
lates miR-124, miR-148a, and miR-130a to inﬂuence tumor growth
and chemo-resistance [11,13e15].
miRNAs are small, non-coding RNA molecules that are highly
conserved across species and play key roles as regulators of gene
expression [16,17]. miRNAs regulate as much as 60% of human
protein coding genes andmodulate the level of proteins involved in
most biological processes, including cancer development, pro-
gression, invasion, and chemo-resistance [7,18]. In cancers,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The expression levels of miR-181a, IL-1b, and NF-kB (RelA) are up-regulated in colon cancer and are positively correlated. By using real-time PCR, the expression levels
of miR-181a, IL-1b, and NF-kB (RelA) in 33 paired samples were analyzed. (A) Signiﬁcantly higher levels of miR-181a, IL-1b, and RelA expression in the tumor samples were found
relative to the levels in the adjacent normal tissues (P < 0.0001).(B) A positive correlation existed between the miR-181a level and the IL-1bmRNA level, the miR-181a level and the
RelA mRNA level, and the IL-1bmRNA level and the RelA mRNA level. (C) Compared with the immortalized colon cancer cell line, HCoEpiC, miR-181a, IL-1b, and NF-kB expression in
all six colon cancer cell lines were higher. The data are presented as mean ± SD of three independent experiments.
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account of its correlation with inﬂammation and cancer chemo-
resistance [19,20]. Liu et al. suggested that the LPS-TLR4-miR-
181a signaling pathway plays a signiﬁcant role in pancreatic cancer
invasion and progression [21]. miR-181a confers cervical cancer
resistance to radiation therapy through targeting the pro-apoptotic
PRKCD gene [22]. Moreover, stable transfection of CRC cell lines
with miR-181a promoted cell motility and invasion as well as tu-
mor growth and liver metastasis, while silencing its expression
resulted in reduced migration and invasion [23]. However, whether
the expression level of miR-181a can be regulated by IL-1b/NF-kB
during CRC growth has not been determined.
In this work, we found that miR-181a induction upon IL-1bsti-
mulation was dependent on the activation of NF-kB, which
enhanced miR-181a gene transcription. Moreover, the upregulated
miR-181a directly targeted phosphatase and tensin homolog
(PTEN) and negatively regulated its expression, which resulted in
promotion of cell survival upon IL-1b induction.
2. Materials and methods
2.1. Tissue samples, cell lines, and plasmids transfection
A total of 33 pairs of primary colon cancer and their matched
adjacent normal tissues were collected. All samples were obtained
from patients who underwent surgical resections at Xiangya Hos-
pital of Central South University (Changsha, China), snap-frozen in
liquid nitrogen, and then stored at 80 C for further use. This
project was approved by the Ethics Committee of Xiangya Hospital
of Central South University.
Seven human cell lines, including ﬁve colon cancer cell lines
(LoVo, SW480, SW620, SW116, and HCT116) and two human colonimmortalized cell lines(HCoEpiC and U6), were purchased from
American Type Culture Collection (ATCC). Cells were grown
routinely in RPMI-1640 medium (Invitrogen, CA, USA) supple-
mented with 10% fetal bovine serum (Gibco, CA, USA) and cultured
in a 37 C humidiﬁed atmosphere of 5% CO2. Ectopic expression of
miR-181a in cells was achieved by transfection with miR-181a
mimics (Genepharma, Shanghai, China) using Lipofectamine2000
(Invitrogen, CA, USA). Overexpression of PTENwas performed using
a PTENORF expression clone (GeneCopoecia, Guangzhou, China).
Cells were transfected for 24 h or 48 h. Transfected cells were used
for further assays or RNA/protein extraction.2.2. RNA extraction and SYBR green quantitative PCR analysis
Total RNA was extracted using Trizol reagent (Invitrogen, CA,
USA). Mature miR-181a expressions in cells were detected using a
Hairpin-it TM miRNAs qPCR kit (Genepharma, Shanghai, China).
Expression of U6 was used as an endogenous control. PTEN
expression was measured by a SYBR green qPCR assay (Takara,
Dalian, China). Data were processed using the 2DDCT method.2.3. CCK-8 cell proliferation assay
Cell proliferation rates were measured using Cell Counting Kit-8
(CCK-8) (Beyotime, Hangzhou, China). In each 96-well plate,
0.5  104 cells were seeded for 24 h, transfected with the indicated
miRNA or siRNA, and further incubated for 24 h, 48 h, 72 h and 96 h,
respectively. Ten microliters of CCK-8 reagent were added to each
well for 1 h before the endpoint of incubation. An OD450nm value in
each well was determined using a microplate reader.
Fig. 2. IL-1b-induced NF-kB activation is required for miR-181a induction. (A) Real-time PCR results showed that IL-1b could induce miR-181a expression. (B) Western blot
showed the level of NF-kB was decreased when transfected with NF-kB-siRNA. (C) Knocking down NF-kB by NF-kB-siRNA signiﬁcantly decreased miR-181a expression. (D) IL-1b-
induced miR-181a upregulation was attenuated in the presence of NF-kB-siRNA. The data are presented as mean ± SD of three independent experiments.
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BrdU assays were performed to determine DNA synthesis at 24 h
and 48 h after transfecting Lovo cells and SW480 cells with miR-
181a mimics or mimics negative control (NC). The infected cells
were cultured for 24 h or 48 h and incubated with a ﬁnal concen-
tration of 10 mM BrdU (BD Pharmingen, San Diego, CA, USA) for
2 he24 h. At the end of the incubation period, the medium was
removed, and the cells were ﬁxed for 30 min at RT, incubated with
peroxidase-coupled anti-BrdU-antibody (Sigma-Aldrich) for
60 min at RT, washed with PBS, and incubated with peroxidase
substrate (tetramethyldbenzidine) for 30 min. Then, the absor-
bance values were measured at 490 nm.
2.5. Western blot analysis
Immunoblotting was performed to detect the expression of NF-
kB and PTEN in colon cell lines. Cultured or transfected cells were
lysed in RIPA buffer with 1% PMSF. Protein was loaded onto a SDS-
PAGE minigel and transferred onto PVDF membrane. After being
probed with 1:1000 diluted rabbit polyclonal p65, NF-kB or PTEN
antibody (Abcam, MA, USA) at 4 C overnight, the blots were sub-
sequently incubated with HRP-conjugated secondary antibody
(1:5000). Signals were visualized using ECL substrates (Millipore,
MA, USA). b-actin was used as an endogenous protein for
normalization.
2.6. Luciferase reporter assay
LoVo and SW480 cells were transfected with miR-181a and
pGL3 luciferase reporter constructs harboring the miR-181a target
sequence. After 24 h, the activities of ﬁreﬂy luciferase and renilla
luciferase in the cell lysates were measured with the Dual-
Luciferase Assay System (Promega, Madison, WI, USA). For the
luciferase transcription reporter assay, miR-181a gene promotersequences (WT or site deletion) were cloned into the promoter
region of the pGL3-Basic vector, and luciferase activity was
measured as described above.
2.7. Statistical analysis
All data from 3 independent experiments were expressed as
mean ± SD and processed using SPSS17.0statistical software. The
expression of miR-181a in colon tissues and their matched adjacent
normal bone and myeloid tissues were compared by Wilcoxon’s
paired test. The difference among the groups in migration and in-
vasion assay was estimated by Student’s t-test or one-way ANOVA.
A P value of<0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. The expression levels of miR-181a, IL-1b, and NF-kB (RelA) are
up-regulated in colon cancer and are positively correlated
By using real-time PCR, we analyzed the expression levels of
miR-181a, IL-1b, and NF-kB (RelA) in 33 paired samples. Signiﬁ-
cantly higher levels of miR-181a, IL-1b, and RelA expression in the
tumor samples were found relative to the levels in the adjacent
normal tissues (p < 0.0001) (Fig. 1A). We observed a positive cor-
relation between themiR-181a level and IL-1bmRNA level, the miR-
181a level and RelAmRNA level, and the IL-1bmRNA level and RelA
mRNA level (Fig. 1B). Compared with the immortalized colon can-
cer cell line, HCoEpiC, miR-181a, IL-1b, and NF-kB expressions in all
six colon cancer cell lines were higher (Fig. 1C).
3.2. IL-1b-induced NF-kB activation is required for miR-181a
induction
Recently, emerging evidence has conﬁrmed that IL-1b activates
NF-kB [24]. To determine the mechanism involved in miR-181a
Fig. 3. Expression of PTEN is negatively regulated by miR-181a. (A) The transfection efﬁciency of miR-181a mimics on miR-181 expression was veriﬁed by real-time PCR and the
expression level of miR-181a was up-regulated by miR-181a mimics by 40 times compared with U6 and blank cells. (B) Enhanced miR-181a expression in LoVo and SW480 cells
signiﬁcantly repressed PTEN mRNA expression compared with the mimics NC group. (C) Enhanced miR-181a expression in LoVo and SW480 cells signiﬁcantly repressed PTEN
protein expression compared with NC. (D) A point mutation in the miR-181a binding site of the PTEN reporter luciferase was constructed, and then mimic NC and miR-181amimics
were co-transfected into LoVo cells and SW480 cells. (E) Compared with wild-type reporter plasmid, the luciferase mut-PTEN reporter was found to be 1.5 times more active, and
similar results were obtained by transfection of reporter plasmid into the SW480 cell line. (F) Forced expression of PTEN partially restored the PTEN protein expression inhibited by
miR-181a. The data are presented as mean ± SD of three independent experiments.
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in the present study. It was observed that IL-1b could induce miR-
181a expression (Fig. 2A). To explore whether NF-kB activity was
present in LoVo and SW480 cells treated with IL-1b, we used a
Western blot to determine the level of NF-kB when transfected
with NF-kB-siRNA (Fig. 2B). Results showed that NF-kB expression
was signiﬁcantly down-regulated by NF-kB-siRNA transfection
compared to Con-siRNA (Fig. 2B, Fig. S1). As expected, we observed
that knocking down NF-kB signiﬁcantly decreased miR-181a
expression (Fig. 2C) and that IL-1b-induced miR-181a upregula-
tionwas attenuated in the presence of NF-kB-siRNA (Fig. 2D). These
results suggested that NF-kB dependent IL-1b treatment was
required for regulation of miR-181a.
3.3. PTEN expression is negatively regulated by miR-181a
To identify the targets of miR-181a, genes that were predicted by
at least ﬁve of eleven databases (Diana, microinspector, miranda,
mirtarget2, mitarget, nbmirtar, pictar, pita, rna22, rnahybrid, and
targetscan) were selected as putative targets. To conﬁrm whether
PTEN is the predicted direct target of miR-181a, we transfected
LoVo and SW480 cells withmiR-181amimics ormimics NC, and the
transfection efﬁciency was veriﬁed by real-time PCR (Fig. 3A).Moreover, enhanced miR-181a expression in LoVo and SW480 cells
signiﬁcantly repressed PTEN mRNA expression compared with NC
(Fig. 3B). Consistently, PTEN protein expression was reduced in
response to miR-181a overexpression (Fig. 3C, Fig. S2A). To
demonstrate the speciﬁc effect of miR-181a, we constructed a
mutation point in the miR-181a binding site of the PTEN reporter
luciferase and co-transfected mimic NC and miR-181amimics into
LoVo cells and SW480 cells (Fig. 3D). Results showed that compared
with the wild-type reporter plasmid, the luciferase mut-PTEN re-
porter was found to be 1.5 times more active, and similar results
were obtained by transfecting reporter plasmid into the SW480 cell
line (Fig. 3E). Moreover, forced expression of PTEN partially
restored the PTEN protein expression inhibited by miR-181a
(Fig. 3F, Fig. S2B). Taken together, these results indicate that miR-
181a plays a critical role in repressing PTEN expression by target-
ing its 30 UTR.
3.4. Induction of miR-181a promotes cell proliferation via targeting
PTEN
In a previous study, PTEN was reported to be one of the most
frequently inactivated tumor suppressor genes. Overexpression of
PTEN in different mammalian tissue culture cells affects various
Fig. 4. Induction of miR-181a promotes cell proliferation via targeting PTEN. (A and C) CCK-8 and BrdU assays were used to determine the proliferation of LoVo and SW480 cells.
In both LoVo and SW480 cells, the proliferation of miR-181a mimics transfected cells was signiﬁcantly enhanced compared to that of the NC mimics control group. When the miR-
181a mimics and pcDNA3.1-PTEN plasmids were co-transfected into cells, the cell proliferation rate was decreased. (B and D) 48 h after transfection of LoVo and SW480 cells, the
transfection efﬁciency of BrdU in miR-181a transfected cells was increased by 25% compared with the control group of mimic NC transfected cells. The incorporation rate of BrdU
was decreased by 12.5% in pcDNA3.1-PTEN transfected cells, whereas the incorporation rate of BrdU was partly recued in cells co-transfected with miR-181a mimics and pcDNA3.1-
PTEN. The data are presented as mean ± SD of three independent experiments.
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CCK-8 and BrdU assays were used to determine the proliferation of
LoVoandSW480cells. InbothLoVoandSW480cells, theproliferation
of miR-181a mimics transfected cells was signiﬁcantly enhanced
compared to thatof theNCmimics control group.When themiR-181a
mimics and pcDNA3.1-PTEN plasmids were co-transfected into cells,
the cell proliferation rate was decreased (Fig. 4A and C). Forty-eight
hours after transfection of LoVo and SW480 cells, the transfection
efﬁciency of BrdU inmiR-181a transfected cells was increased by 25%
compared with the control group of mimic NC transfected cells. The
incorporation rate of BrdUwasdecreased by 12.5% inpcDNA3.1-PTEN
transfected cells, whereas the incorporation rate of BrdU was partly
rescued in cells co-transfectedwithmiR-181amimics and pcDNA3.1-
PTEN (Fig. 4B and D). Taken together, proliferation was enhanced in
both LoVo and SW480 cells transfected with miR-181a mimics,
whereas proliferation was decreased with overexpression of PTEN.
Meanwhile, the pro-survival effect ofmiR-181awas partly blocked by
co-transfection with exogenous PTEN, suggesting that PTEN repres-
sionmay play amajor role inmiR-181a-dependentprotection in cells.3.5. Inhibition of miR-181a/NF-kB restores PTEN repression by IL-1b
To conﬁrm the role of miR-181a and NF-kB in IL-1b induced
PTEN repression, miR-181a/NF-kB inhibition was achieved, and the
expression level of PTENwas determined. Results showed thatIL-1b
induced NF-kB expression but reduced PTEN expression on the
protein level (Fig. 5A, Fig. S3A). Inhibition of miR-181awas achievedby miR-181a inhibitor, and the inhibitory efﬁciency was veriﬁed by
real-time PCR (Fig. 5B). Moreover, results from Western blot anal-
ysis showed that PTEN repression induced by IL-1bcould be
restored by either miR-181a or NF-kB inhibition (Fig. 5C and D,
Fig. S3B and C). In conclusion, these results suggest that NF-kB
dependent IL-1b stimulation is required for CRC cell growth regu-
lation, most likely through regulation of the miR-181a/PTEN axis.4. Discussion
IL-1 is a major pro-inﬂammatory cytokine that is produced by
malignant ormicro environmental cells [26]. IL-1 also functions as a
pleiotropic cytokine involved in tumorigenesis and tumor inva-
siveness; therefore, it represents a feasible candidate for a modu-
latory cytokine that can tilt the balance between inﬂammation and
immunity toward the induction of antitumor responses [27].
NF-kB is one of the most important intracellular nuclear tran-
scription factors, and it plays a central role in the transcriptional
regulation of many genes that are inﬂuenced by various stimuli
[28,29]. Recently, NF-kB has been shown to regulate miRNA
expression, and in turn, some miRNAs modulate NF-kB expression
directly or indirectly [28,30e32]. Emerged evidence has conﬁrmed
that some inﬂammation-related cytokines activate NF-kB,
including IL-1b [33,34].
miRNA regulation by the inﬂammatory pathway is important for
the regulation of colon cancer cell growth [5]. In the present study,
real-time PCR results detected higher levels of IL-1b, NF-kB (RelA),
Fig. 5. Inhibition of miR-181a/NF-kB restores PTEN repression by IL-1b. (A) IL-1b induced NF-kB expression but reduced PTEN expression on the protein level. (B) Inhibition of
miR-181a was achieved with a miR-181a inhibitor and the inhibitory efﬁciency was veriﬁed by real-time PCR. (C and D) Results from Western blot analysis showed that PTEN
repression induced by IL-1b could be restored by either miR-181a or NF-kB inhibition. (E) A ﬂow chart of the IL-1b/NF-kB/miR-181a/PTEN pathway that may contribute to CRC
progression. The data are presented as mean ± SD of three independent experiments.
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subjects and immortalized cell lines. In addition, we ﬁrst observed a
positive correlation between the miR-181a level and the IL-1b
mRNA level, the miR-181a level and the RelA mRNA level, and the
IL-1b mRNA level and the RelA mRNA level.
To verify whether IL-1bregulates miR-181a expression through
NF-kB, NF-kB activity was examined in the present study. We found
thatmiR-181a expression was promoted by IL-1b but reduced by
knocking down NF-kB. In addition, NF-kB inhibition restored pro-
motion of miR-181a expression by IL-1b. These data revealed that
IL-1bregulates miR-181a expression through NF-kB. However, the
role of this regulation progression in CRC cell growth and the un-
derlying mechanism was still unclear.
PTEN is an omnipresent tumor-suppressor gene, and its dysre-
gulation results in many solid tumors [35,36]. Targeted deletion of
PTEN leads to the development of colon cancer [37]. In addition, IL-
1band NF-kB signiﬁcantly enhance PTEN repression [38]. Accu-
mulating evidence suggests that NF-kB regulates PTEN in cancers,
directly or indirectly through miRNAs [39,40]. On the other hand,
PTEN has been reported to be regulated by inﬂammatory factors,such as LPS, TNF-a and IL-6 [21,39,41]. In the present study, it has
been revealed that PTEN expression on both the mRNA and protein
levels were signiﬁcantly down-regulated in response to miR-181a
overexpression. In addition, bioinformatics studies suggest that a
target site of miR-181a is in the 30UTR of PTENmRNA. Given that IL-
1bregulates miR-181a expression through NF-kB, it was assumed
thatIL-1b/NF-kB regulates PTEN by miR-181a directly targeting its
30UTR.To conﬁrm the assumption, we ﬁrst cloned the 30UTR of PTEN
into the pMIR-REPORT luciferase reporter and found that miR-181a
signiﬁcantly inhibited PTEN expression by directly binding to the
30UTRof PTEN, consistent with a previous study by Wei et al. that
demonstrates that miR-181a mediates a metabolic shift in colon
cancer cells via the PTEN/AKT pathway [37].
To detect the speciﬁc role of the miR-181a/PTEN axis in CRC
progression, proliferation of LoVo and SW480 cells was assessed.
Results showed that proliferation was enhanced in both LoVo and
SW480 cells transfected with miR-181a mimics, whereas prolifer-
ation decreased with overexpression of PTEN. Meanwhile, the pro-
survival effect of miR-181a was partly blocked by co-transfection
with exogenous PTEN, suggesting that PTEN repression may play
P. Hai ping et al. / Archives of Biochemistry and Biophysics 604 (2016) 20e2626a major role in miR-181a-dependentprotection in cells.
Moreover, to conﬁrm the role of miR-181a and NF-kB in IL-1b
induced PTEN repression, miR-181a/NF-kB inhibition was achieved
and the expression levels of PTEN were then determined. Results
showed that compared with the control group, PTEN repression
induced by IL-1b was restored by either miR-181a or NF-kB inhi-
bition. All the above results suggest that IL-1b/NF-kB regulates the
miR-181a/PTEN axis in CRC progression, which plays a major role in
CRC growth and progression.
Taken together, our data might provide new insights into the
pathophysiological mechanism of CRC and suggest a novel drug
target for CRC treatment. Furthermore, overexpression of PTEN in
LoVo and SW480 cells could reverse the effect of miR-181a and IL-
1bto restore the proliferation of LoVo and SW480 cells. In conclu-
sion, our observations indicated that the NF-kB/miR-181a/PTEN
pathway upon IL-1b treatment contributes to malignancy.
5. Conclusion
In the present study, we identiﬁed anIL-1b/NF-kB/miR-181a/
PTEN pathway that may contribute to CRC progression and repre-
sents a novel potential therapeutic target for treating CRC.
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